We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+9.34%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$612M
AUM Growth
+$115M
(+23%)
Cap. Flow
+$88.3M
Cap. Flow
% of AUM
14.44%
Top 10 Holdings %
Top 10 Hldgs %
8.98%
Holding
532
New
97
Increased
238
Reduced
88
Closed
80
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Telecom Argentina
TEO
|
+$2.03M |
| 2 |
Methanex
MEOH
|
+$1.43M |
| 3 |
EQM
EQM Midstream Partners, LP
EQM
|
+$1.32M |
| 4 |
Carlyle Secured Lending
CGBD
|
+$1.31M |
| 5 |
The GEO Group
GEO
|
+$1.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oxford Square Capital
OXSQ
|
+$2.73M |
| 2 |
MPLX
MPLX
|
+$1.51M |
| 3 |
MDCO
Medicines Co
MDCO
|
+$982K |
| 4 |
Gladstone Investment Corp
GAIN
|
+$857K |
| 5 |
CELG
Celgene Corp
CELG
|
+$712K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 20.46% |
| 2 | Real Estate | 16.88% |
| 3 | Energy | 14.34% |
| 4 | Healthcare | 10.85% |
| 5 | Materials | 9.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Travere Therapeutics
TVTX
$5.33B
| $632K | 0.1% |
44,525
+8,428
| +23% | +$108K |
|
177
Exelixis
EXEL
$13.9B
| $631K | 0.1% |
35,810
+632
| +2% | +$10.7K |
|
178
Gilead Sciences
GILD
$161B
| $631K | 0.1% |
9,704
-1,328
| -12% | -$86.5K |
|
179
Ligand Pharmaceuticals
LGND
$6.02B
| $627K | 0.1% |
9,642
-705
| -7% | -$47.1K |
|
180
United Therapeutics
UTHR
$26.3B
| $627K | 0.1% |
7,121
-1,735
| -20% | -$153K |
|
181
Vanda Pharmaceuticals
VNDA
$312M
| $626K | 0.1% |
38,136
-9,334
| -20% | -$141K |
|
182
Alnylam Pharmaceuticals
ALNY
$36.3B
| $625K | 0.1% |
5,424
-4,464
| -45% | -$445K |
|
183
Sarepta Therapeutics
SRPT
$1.66B
| $624K | 0.1% |
4,833
-961
| -17% | -$97K |
|
184
Neurocrine Biosciences
NBIX
$17.7B
| $620K | 0.1% |
5,771
-2,479
| -30% | -$260K |
|
185
Acadia Pharmaceuticals
ACAD
$4.25B
| $616K | 0.1% |
14,396
-14,167
| -50% | -$616K |
|
186
Ionis Pharmaceuticals
IONS
$9.35B
| $611K | 0.1% |
10,116
-1,040
| -9% | -$62K |
|
187
Incyte
INCY
$23.5B
| $608K | 0.1% |
6,967
-1,944
| -22% | -$166K |
|
|
ONC
188
BeOne Medicines Ltd
ONC
$33.8B
| $601K | 0.1% |
3,625
+1,470
| +68% | +$244K |
|
189
Halozyme
HALO
$9.72B
| $596K | 0.1% |
33,612
-10,434
| -24% | -$181K |
|
190
Enanta Pharmaceuticals
ENTA
$372M
| $592K | 0.1% |
9,576
+1,497
| +19% | +$92.8K |
|
191
Quince Therapeutics
QNCX
$17.5M
| $592K | 0.1% |
+53
| New | +$320K |
|
|
IMGN
192
DELISTED
Immunogen Inc
IMGN
| $587K | 0.1% |
115,075
-12,521
| -10% | -$42.5K |
|
|
PTLA
193
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $579K | 0.09% |
24,255
-2,655
| -10% | -$73.2K |
|
|
RDUS
194
DELISTED
Radius Health, Inc.
RDUS
| $575K | 0.09% |
28,509
-2,989
| -9% | -$72.6K |
|
|
EPZM
195
DELISTED
Epizyme, Inc
EPZM
| $572K | 0.09% |
23,272
+1,552
| +7% | +$23K |
|
|
AKCA
196
DELISTED
Akcea Therapeutics Inc
AKCA
| $560K | 0.09% |
33,059
+21,948
| +198% | +$408K |
|
197
Precision BioSciences
DTIL
$188M
| $556K | 0.09% |
+1,335
| New | +$419K |
|
|
SWTX
198
DELISTED
SpringWorks Therapeutics
SWTX
| $549K | 0.09% |
+14,253
| New | +$334K |
|
199
Lexicon Pharmaceuticals
LXRX
$1.02B
| $545K | 0.09% |
131,286
+8,632
| +7% | +$33.2K |
|
|
PRVB
200
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $523K | 0.09% |
+35,118
| New | +$313K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, Virtus ETF Advisers held 532 positions worth $612M, up 23% from $496M the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Virtus ETF Advisers deployed $88.3M of net new capital in Q4 2019, opening 97 new positions and adding to 238 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 14,229 shares worth $462K.
By sector, the portfolio is most concentrated in Financials at 20% of assets, down from 24% a quarter earlier, followed by Real Estate and Energy.
On the sell side, the largest reduction was Oxford Square Capital, an estimated $2.73M trimmed.
- Virtus ETF Advisers's largest Q4 2019 buy was Odonate Therapeutics, Inc. Common Stock: 14,229 shares worth $462K.
- Virtus ETF Advisers added most to Telecom Argentina in Q4 2019, an estimated $2.03M increase.
- Virtus ETF Advisers's biggest Q4 2019 reduction was Oxford Square Capital, cutting an estimated $2.73M.
- Virtus ETF Advisers fully exited Medicines Co in Q4 2019, selling an estimated $982K.
- Virtus ETF Advisers's ten largest holdings make up 9% of its $612M portfolio in Q4 2019.
- Virtus ETF Advisers opened 97 new positions and closed 80 in Q4 2019.
- Virtus ETF Advisers's portfolio value rose 23% quarter-over-quarter to $612M.
Based on Virtus ETF Advisers's 13F filing for Q4 2019, filed 13 Feb 2020.